BioSpace News Archive

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.

Intrinsic Therapeutics, Inc., a medical device company focused on delivering safe treatments to improve surgical efficacy, announced growing enthusiasm among physicians for its Barricaid technology, which manages lumbar disc herniation.

Sensor Electronic Technology, Inc., the World’s first compound semiconductor for UV LED solutions and Seoul Viosys ’ subsidiary, announced that it launches portable air purifiers of brand “VAC” and surface disinfection devices of brand “VSM+” with Violeds technology to reduce infection from various harmful bacteria including new coronavirus.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 15,200 shares of Calithera’s common stock, at a per share exercise price of $5.82, the closing trading price on May 29, 2020.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies 2020 Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Wednesday, June 3, 2020 at 10:00 AM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media sec

Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as Principal Investigator

Technopath Clinical Diagnostics announced that it is rolling out COVID-19 antibody testing in Ireland to help businesses navigate a safer workplace re-entry.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 147,500 shares of BioCryst common stock on May 29, 2020 as inducements material to each employee entering into employment with BioCryst.

Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis Study met primary endpoints of clinical remission in induction at Week 10 and in maintenance at Week 52 Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study P

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave of 30 U.S. patients to be followed by a broad rollout to all U.S. patients in the coming months. Novocure prioritized and accelerate